Fulgent Genetics Inc
Fulgent Genetics Inc logo
FLGT

Fulgent Genetics Inc (FLGT)

$35.930.77%

Market is closed
– opens on 8 PM, 06 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$35.2
Day's Range
$36.12
$31.07
52-Week Range
$109.55
1 month return1.15%
3 month return15.2%
1 year return56.15%
5 year return929.51%

Company Information

Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing ('NGS') with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company's advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus ('COVID-19'), including NGS and reverse transcription polymerase chain reaction ('RT-PCR') - based tests. The Company has received Emergency Use Authorization ('EUA') from the U.S. Food and Drug Administration ('FDA') for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Company's business is its ability to provide expansive options and flexibility for all clients' unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.
OrganizationFulgent Genetics Inc
Employees645
CEOMr. Ming Hsieh
IndustryHealth Services

Analyst Recommendation

based on 2 analysts ratings

Buy
50%
Buy
50%
Hold
0%
Sell

Based on 2 Wall street analysts offering stock ratings for Fulgent Genetics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 48.43%

Current

$35.93

Target

$53.33

Recommendation Trend

Based on 2 analyst

Current1M Ago3M Ago
Buy
1
7
6
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.1B
Book Value
$43.03
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
8.32
PE Ratio
4.29
PEG Ratio
1.32
Wall Street Target Price
53.33

Valuation

Trailing PE4.29
Forward PE7.94
Price/Book (mrq)
0.86
Enterprise Value
543.9M
Enterprise Value/Revenue
0.68
Enterprise Value/Ebitda
1.38

Technicals

Beta
1.54
50 Day MA
37.4
200 Day MA
50.26

Institutional Holdings

BlackRock Inc

11.53%

Vanguard Group Inc

4.52%

State Street Corporation

2.5%

Dimensional Fund Advisors, Inc.

2.25%

Geode Capital Management, LLC

1.27%

Amvescap Plc.

1.22%

Discover more

Frequently Asked Questions

What is Fulgent Genetics Inc share price today?

Can Indians buy Fulgent Genetics Inc shares?

How can I buy Fulgent Genetics Inc shares from India?

Can Fractional shares of Fulgent Genetics Inc be purchased?

What are the documents required to start investing in Fulgent Genetics Inc stocks?

What are today’s High and Low prices of Fulgent Genetics Inc?

What are today’s traded volumes of Fulgent Genetics Inc?

What is today’s market capitalisation of Fulgent Genetics Inc?

What is the 52 Week High and Low Range of Fulgent Genetics Inc?

How much percentage Fulgent Genetics Inc is down from its 52 Week High?

How much percentage Fulgent Genetics Inc is up from its 52 Week low?

What are the historical returns of Fulgent Genetics Inc?

Who is the Chief Executive Officer (CEO) of Fulgent Genetics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*